Tüdőrák: vizsgálatok itt: Spanyolország
275 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 17.. Ask the study team whether a trial fits you.
- No phaseTaking peopleA Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
- Where
- A Coruña, Burgos, Córdoba, Jerez de la Frontera, Lugo, Málaga, Ourense, Palma de Mallorca, Santiago de Compostela, Seville, Valladolid, Vigo
- Életkor
- 18 év and over
- People
- 380 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07230691 - 2. fázisTaking peopleStudy to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Where
- A Coruña, Badalona, Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Logrono, Madrid, Málaga, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00 - 2. fázisTaking peopleA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- Where
- Alicante, Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 68 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07586202 - 2/3. fázisTaking peopleSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Where
- A Coruna, Badajoz, Badalona, Barcelona, Castello De La Plana, Las Palmas de Gran Canaria, León, L'Hospitalet de Llobregat, Lleida, Madrid, Majadahonda, Málaga, San Cristobal De La Laguna, Santander, Sevilla, Valencia, Vigo, Zaragoza
- Életkor
- 18 év and over
- People
- 1580 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00 - 3. fázisNot yet taking people in SpanyolországClinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Where
- Barcelona, Castello De La Plana, Elche, Girona, Las Palmas De Gran Canaria, Lleida, Madrid, Málaga, Murcia, Pamplona, Sevilla, Torrejón de Ardoz, Valencia, Vigo
- Életkor
- 18 év to 90 év
- People
- 507 worldwide
- Run by
- ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00 - 3. fázisTaking peopleStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Where
- Barcelona, Málaga, Oviedo, Palma, Valencia
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- ArriVent BioPharma, Inc.
See details and how to joinNCT07185997 - 3. fázisTaking peopleBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Where
- Barcelona, Burgos, Elche, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Pamplona, Reus, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00 - 2. fázisTaking peopleA Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
- Where
- Alicante, Badalona, Barcelona, Logroño, Málaga, Murcia, San Sebastián de los Reyes, Sevilla
- Életkor
- 18 év and over
- People
- 50 worldwide
- Run by
- Puma Biotechnology, Inc.
See details and how to joinNCT07465757 · EU 2026-525382-47-00 - 2/3. fázisTaking peoplePhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- A Coruña, Badalona, Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Santiago De Compostela, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00 - 1. fázisTaking peoplePhase 1 Study of MK-1084 in KRAS mutant advanced solid tumors
- Where
- Barcelona, Madrid, Pamplona
- Életkor
- 18 év and over
- People
- 214 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05067283 · EU 2022-501563-40-00 - 1/2. fázisTaking peopleFirst-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- Where
- Barcelona, Logroño, Madrid, Málaga, Sevilla
- Életkor
- 18 év and over
- People
- 345 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT06043817 · EU 2023-506759-51-00 - 1/2. fázisBefejeződöttKEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Where
- L'Hospitalet de Llobregat, Pozuelo de Alarcón
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04165070 · EU 2023-506932-33-00 - No phaseTaking peopleKEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Életkor
- 18 év and over
- People
- 1065 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04165798 - 3. fázisTaking peopleA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Alcorcón, Ávila, Barcelona, Fuenlabrada, Jaén, Las Palmas de Gran Canaria, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00 - 1/2. fázisTaking peopleStudy of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- Where
- Badalona, Barcelona, L'Hospitalet de Llobregat, Logroño, Madrid, Málaga, Pamplona, Sevilla
- Életkor
- 18 év and over
- People
- 364 worldwide
- Run by
- Synthekine
See details and how to joinNCT05098132 · EU 2025-522632-14-00 - 3. fázisTaking peoplePembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Where
- Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Santiago de Compostela, Sevilla
- Életkor
- 18 év and over
- People
- 851 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Where
- Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Lleida, Madrid, Majadahonda, Sevilla
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00 - 2. fázisNot yet taking people in SpanyolországDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Logrono
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - 1. fázisTaking peopleA Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 404 worldwide
- Run by
- Astellas Pharma Inc
See details and how to joinNCT07094204 · EU 2025-522082-29-00 - 2. fázisTaking peopleA randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations
- Where
- Alcorcón, Badalona, Sabadell, Hospital de La Santa Creu Isant Pau
- Életkor
- 18 év and over
- People
- 189 worldwide
- Run by
- Fondazione Ricerca Traslazionale
See details and how to joinNCT04811001 · EU 2024-518223-29-00 - 3. fázisTaking peoplePhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Where
- Alicante, Barcelona, Jerez de la Frontera, Reus
- Életkor
- 18 év and over
- People
- 675 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- Where
- Barcelona, Castello De La Plana, Las Palmas de Gran Canaria, Madrid, Majadahonda, Sevilla
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00 - 1/2. fázisTaking peopleA Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- Where
- Barcelona, Madrid, Málaga, PAU de Sanchinarro, Pozuelo de Alarcón, Seville, Valencia
- Életkor
- 18 év and over
- People
- 235 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00 - 3. fázisTaking peopleA Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
- Where
- A Coruna, Alicante, Barakaldo, Barcelona, Granada, Jerez de la Frontera, Madrid, Santa Cruz de Tenerife, Valencia
- Életkor
- 18 év and over
- People
- 390 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT06931717 · EU 2024-519901-36-00 - 1/2. fázisTaking peopleA Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Valencia
- Életkor
- 18 év and over
- People
- 152 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01